Pub Date : 2024-11-06DOI: 10.1016/j.jhep.2024.10.039
Valentin Coirier, Florent Artru, Christophe Camus
Section snippets
Declaration of Competing Interest
none
Financial disclosure
none
Author contributions
all authors contributed equally to the manuscript in terms of concept, writing, editing.
章节片段竞争利益声明无财务披露无作者贡献所有作者在构思、写作和编辑方面对稿件做出了同等贡献。
{"title":"Late use of Plasma Exchange in Acute Liver Failure: The Battle is Lost?","authors":"Valentin Coirier, Florent Artru, Christophe Camus","doi":"10.1016/j.jhep.2024.10.039","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.10.039","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Declaration of Competing Interest</h2>none</section></section><section><section><h2>Financial disclosure</h2>none</section></section><section><section><h2>Author contributions</h2>all authors contributed equally to the manuscript in terms of concept, writing, editing.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"552 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142588327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.jhep.2024.10.024
Jessica Ann Musto, Randall Brown, Michael Ronan Lucey
In order to understand and curb the harms related to alcohol, it will be necessary to think beyond patterns of use that meet criteria for a diagnosis of alcohol use disorder, or addiction. Current research suggests that regular daily alcohol use does not confer a health benefit, and for many persons, even relatively low consumption is associated with a health risk. Determining a safe limit for alcohol consumption is challenging both for the individual person and for society. We conclude that excessive drinking is always risky. We provide a list of circumstances, such as chronic illness, driving a vehicle, or pregnancy where persons should be advised to abstain from alcohol. We recognize the need to encourage less consumption of alcohol, particularly in young adults, and in older adults with co-morbid conditions particularly when taking multiple medications. Finally, we offer the modest proposal that, for persons without the contributing negative influences described above, consumption which adheres to one drink per session, with interspersed abstinent days, does not constitute a meaningful risk to health.
{"title":"Is there a safe limit for consumption of alcohol?","authors":"Jessica Ann Musto, Randall Brown, Michael Ronan Lucey","doi":"10.1016/j.jhep.2024.10.024","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.10.024","url":null,"abstract":"In order to understand and curb the harms related to alcohol, it will be necessary to think beyond patterns of use that meet criteria for a diagnosis of alcohol use disorder, or addiction. Current research suggests that regular daily alcohol use does not confer a health benefit, and for many persons, even relatively low consumption is associated with a health risk. Determining a safe limit for alcohol consumption is challenging both for the individual person and for society. We conclude that excessive drinking is always risky. We provide a list of circumstances, such as chronic illness, driving a vehicle, or pregnancy where persons should be advised to abstain from alcohol. We recognize the need to encourage less consumption of alcohol, particularly in young adults, and in older adults with co-morbid conditions particularly when taking multiple medications. Finally, we offer the modest proposal that, for persons without the contributing negative influences described above, consumption which adheres to one drink per session, with interspersed abstinent days, does not constitute a meaningful risk to health.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"124 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142562215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-31DOI: 10.1016/j.jhep.2024.07.032
European Association for the Study of the Liver, Didier Samuel, EASL Governing Board Representative, Panel members
Liver transplantation (LT) is an established life-saving procedure. The field of LT has changed in the past 10 years from several perspectives, with the expansion of indications, transplantation of patients with acute-on-chronic liver failure, evolution of transplant oncology, the use of donations after cardiac death, new surgical techniques, and prioritisation of recipients on the waiting list. In addition, the advent of organ perfusion machines, the recognition of new forms of rejection, and the attention paid to the transition from paediatric to adult patients, have all improved the management of LT recipients. The purpose of the EASL guidelines presented here is not to cover all aspects of LT but to focus on developments since the previous EASL guidelines published in 2016.
{"title":"EASL Clinical Practice Guidelines on liver transplantation","authors":"European Association for the Study of the Liver, Didier Samuel, EASL Governing Board Representative, Panel members","doi":"10.1016/j.jhep.2024.07.032","DOIUrl":"10.1016/j.jhep.2024.07.032","url":null,"abstract":"<div><div>Liver transplantation (LT) is an established life-saving procedure. The field of LT has changed in the past 10 years from several perspectives, with the expansion of indications, transplantation of patients with acute-on-chronic liver failure, evolution of transplant oncology, the use of donations after cardiac death, new surgical techniques, and prioritisation of recipients on the waiting list. In addition, the advent of organ perfusion machines, the recognition of new forms of rejection, and the attention paid to the transition from paediatric to adult patients, have all improved the management of LT recipients. The purpose of the EASL guidelines presented here is not to cover all aspects of LT but to focus on developments since the previous EASL guidelines published in 2016.</div></div>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"81 6","pages":"Pages 1040-1086"},"PeriodicalIF":26.8,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142556217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-30DOI: 10.1016/j.jhep.2024.10.031
En Ying Tan, Pojsakorn Danpanichkul, Jie Ning Yong, Zhenning Yu, Darren Jun Hao Tan, Wen Hui Lim, Benjamin Koh, Ryan Yan Zhe Lim, Ethan Kai Jun Tham, Kartik Mitra, Asahiro Morishita, Yao-Chun Hsu, Ju Dong Yang, Hirokazu Takahashi, Ming-Hua Zheng, Atsushi Nakajima, Cheng Han Ng, Karn Wijarnpreecha, Mark D. Muthiah, Amit G. Singal, Daniel Q. Huang
Background & Aims
The epidemiology of adult primary liver cancer continues to evolve, related to the increasing prevalence of metabolic disease, rising alcohol consumption, advancements in vaccination for hepatitis B (HBV), and antiviral therapy for hepatitis C (HCV). Disparities in care and the burden of liver cancer between populations persist. We assess trends in the burden of liver cancer and contributions by various etiologies across 204 countries and territories from 2010 to 2021.
Methods
Utilizing the methodological framework of the Global Burden of Disease Study 2021, we analyzed global and regional temporal trends in incidence and mortality, and the contributions of various etiologies of liver disease.
Results
In 2021, there were an estimated 529202 incident cases and 483875 deaths related to liver cancer. From 2010 to 2021, global liver cancer incident cases and deaths increased by 26% and 25%, respectively. Global age-standardized incidence rates (ASIRs) and death rates (ASDRs) for liver cancer declined but rose in the Americas and Southeast Asia. HBV remained the dominant cause of global incident liver cancer cases and deaths. Metabolic dysfunction-associated steatotic liver disease (MASLD) was the only etiology of liver cancer with rising ASIRs and ASDRs. By contrast, ASIRs and ASDRs remained stable for alcohol-related liver cancer, and declined for HBV- and HCV-related liver cancer.
Conclusions
While age-adjusted incidence and deaths from liver cancer have started to decline, the absolute number of incident cases and deaths continues to increase. Population growth and aging contribute to the observed disconnect in the temporal trends of absolute cases and rates. Disparities remain, and MASLD-related liver cancer continues to surge.
{"title":"Liver Cancer in 2021: Global Burden of Disease Study","authors":"En Ying Tan, Pojsakorn Danpanichkul, Jie Ning Yong, Zhenning Yu, Darren Jun Hao Tan, Wen Hui Lim, Benjamin Koh, Ryan Yan Zhe Lim, Ethan Kai Jun Tham, Kartik Mitra, Asahiro Morishita, Yao-Chun Hsu, Ju Dong Yang, Hirokazu Takahashi, Ming-Hua Zheng, Atsushi Nakajima, Cheng Han Ng, Karn Wijarnpreecha, Mark D. Muthiah, Amit G. Singal, Daniel Q. Huang","doi":"10.1016/j.jhep.2024.10.031","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.10.031","url":null,"abstract":"<h3>Background & Aims</h3>The epidemiology of adult primary liver cancer continues to evolve, related to the increasing prevalence of metabolic disease, rising alcohol consumption, advancements in vaccination for hepatitis B (HBV), and antiviral therapy for hepatitis C (HCV). Disparities in care and the burden of liver cancer between populations persist. We assess trends in the burden of liver cancer and contributions by various etiologies across 204 countries and territories from 2010 to 2021.<h3>Methods</h3>Utilizing the methodological framework of the Global Burden of Disease Study 2021, we analyzed global and regional temporal trends in incidence and mortality, and the contributions of various etiologies of liver disease.<h3>Results</h3>In 2021, there were an estimated 529202 incident cases and 483875 deaths related to liver cancer. From 2010 to 2021, global liver cancer incident cases and deaths increased by 26% and 25%, respectively. Global age-standardized incidence rates (ASIRs) and death rates (ASDRs) for liver cancer declined but rose in the Americas and Southeast Asia. HBV remained the dominant cause of global incident liver cancer cases and deaths. Metabolic dysfunction-associated steatotic liver disease (MASLD) was the only etiology of liver cancer with rising ASIRs and ASDRs. By contrast, ASIRs and ASDRs remained stable for alcohol-related liver cancer, and declined for HBV- and HCV-related liver cancer.<h3>Conclusions</h3>While age-adjusted incidence and deaths from liver cancer have started to decline, the absolute number of incident cases and deaths continues to increase. Population growth and aging contribute to the observed disconnect in the temporal trends of absolute cases and rates. Disparities remain, and MASLD-related liver cancer continues to surge.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"126 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142541693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-28DOI: 10.1016/j.jhep.2024.10.028
Zhujun Cao, Yujing Yao, Minghao Cai, Chenxi Zhang, Yuhan Liu, Haiguang Xin, Baoyan An, Hui Wang, Yide Lu, Ziqiang Li, Yaoxing Chen, Yan Huang, Min Xin, Ruokun Li, Zhuping Qian, Yi Zhou, Xiaogang Xiang, Richard Moreau, Qing Xie
Background and aims
In patients with acutely decompensated cirrhosis (ADC) who present with clinically apparent precipitants (i.e., infections, acute liver injury), alterations in blood markers of inflammation associate with progression toward severe phenotypes (e.g., acute-on-chronic liver failure, ACLF). It is unclear whether alterations in blood inflammatory markers may associate with progression of ADC independently of precipitants.
Methods
We prospectively enrolled 394 patients admitted for ADC who were classified into four phenotypes of increasing severity: no organ dysfunction (n=168), organ dysfunction alone (n=72), organ failure without ACLF (n=91), and ACLF (n=63). Clinical blood cell counts and serum levels of inflammatory markers (including soluble markers related to type-1, type-2, and type-3 inflammation) were obtained at enrollment. Ordinal regression with adjacent categories logit model adjusted for confounders (including precipitants) was used to analyze associations between changes in each blood inflammatory marker and the worsening of ADC.
Results
Inflammatory markers that were associated with higher risk of progressing to the next more severe stage were as follows: increasing neutrophil counts (adjusted common odds ratio [cOR] 1.17, 95%CI 1.06-1.28); increasing levels of the type-2 cytokine interleukin (IL)-25 (cOR 1.21, 95%CI 1.06-1.39), type-3 cytokines IL-6 (cOR 1.15, 95%CI 1.02-1.28) and IL-22 (cOR 1.16, 95%CI 1.03-1.30), or anti-inflammatory soluble CD163 (cOR 1.94, 95%CI 1.58-2.38); decreasing lymphocyte counts (cOR 0.77, 95%CI 0.68-0.87), or decreasing levels of the type-1 cytokine IFN-γ (cOR 0.85, 95%CI 0.75-0.95).
Conclusions
Among patients with ADC, alterations in blood levels of cytokines related to type-1, type-2 and type-3 inflammation, together with neutrophilia, lymphopenia and elevated anti-inflammatory signals were individually associated with an increased risk of progressing toward ACLF, independently of the presence of clinically apparent precipitants.
{"title":"Blood markers for type-1,-2, and -3 inflammation are associated with severity of acutely decompensated cirrhosis","authors":"Zhujun Cao, Yujing Yao, Minghao Cai, Chenxi Zhang, Yuhan Liu, Haiguang Xin, Baoyan An, Hui Wang, Yide Lu, Ziqiang Li, Yaoxing Chen, Yan Huang, Min Xin, Ruokun Li, Zhuping Qian, Yi Zhou, Xiaogang Xiang, Richard Moreau, Qing Xie","doi":"10.1016/j.jhep.2024.10.028","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.10.028","url":null,"abstract":"<h3>Background and aims</h3>In patients with acutely decompensated cirrhosis (ADC) who present with clinically apparent precipitants (i.e., infections, acute liver injury), alterations in blood markers of inflammation associate with progression toward severe phenotypes (e.g., acute-on-chronic liver failure, ACLF). It is unclear whether alterations in blood inflammatory markers may associate with progression of ADC independently of precipitants.<h3>Methods</h3>We prospectively enrolled 394 patients admitted for ADC who were classified into four phenotypes of increasing severity: no organ dysfunction (n=168), organ dysfunction alone (n=72), organ failure without ACLF (n=91), and ACLF (n=63). Clinical blood cell counts and serum levels of inflammatory markers (including soluble markers related to type-1, type-2, and type-3 inflammation) were obtained at enrollment. Ordinal regression with adjacent categories logit model adjusted for confounders (including precipitants) was used to analyze associations between changes in each blood inflammatory marker and the worsening of ADC.<h3>Results</h3>Inflammatory markers that were associated with higher risk of progressing to the next more severe stage were as follows: increasing neutrophil counts (adjusted common odds ratio [cOR] 1.17, 95%CI 1.06-1.28); increasing levels of the type-2 cytokine interleukin (IL)-25 (cOR 1.21, 95%CI 1.06-1.39), type-3 cytokines IL-6 (cOR 1.15, 95%CI 1.02-1.28) and IL-22 (cOR 1.16, 95%CI 1.03-1.30), or anti-inflammatory soluble CD163 (cOR 1.94, 95%CI 1.58-2.38); decreasing lymphocyte counts (cOR 0.77, 95%CI 0.68-0.87), or decreasing levels of the type-1 cytokine IFN-γ (cOR 0.85, 95%CI 0.75-0.95).<h3>Conclusions</h3>Among patients with ADC, alterations in blood levels of cytokines related to type-1, type-2 and type-3 inflammation, together with neutrophilia, lymphopenia and elevated anti-inflammatory signals were individually associated with an increased risk of progressing toward ACLF, independently of the presence of clinically apparent precipitants.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"25 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142536590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-26DOI: 10.1016/j.jhep.2024.10.032
Zgjim Osmani, Willem Pieter Brouwer, Dwin G.B. Grashof, Youkyung Lim, Michael Doukas, Harry L.A. Janssen, Harmen J.G. van de Werken, Andre Boonstra
<h3>Background & Aims</h3>Chronic HBV patients with concomitant metabolic dysfunction-associated steatohepatitis (MASH) have been shown to develop more advanced fibrosis faster with more severe liver disease as compared to patients with chronic HBV alone. However, our understanding of the underlying mechanisms is limited. Here we study how MASH co-morbidity impact immune activity in the liver of patients with chronic HBV infection.<h3>Methods</h3>Bulk RNA sequencing was performed on liver biopsies from patients with only MASH (n=10), only HBeAg-negative chronic HBV (ENEG; n=11), combined MASH/ENEG (n=9) and healthy controls (n=9). Biopsies with no or minimal fibrosis (≤F2) were selected to avoid confounding effects of fibrosis. We compared whole transcriptome data from patients with MASH/ENEG to those with ENEG alone to determine the impact of MASH co-morbidity on chronic hepatitis B.<h3>Results</h3>There is a high degree of overlap of liver gene expression profiles in patients with only ENEG versus those with only MASH compared to healthy controls, suggesting a largely shared mechanism of liver dysfunction and immune activity for these distinct conditions. In patients with ENEG, MASH co-morbidity significantly reduced interferon pathway activity (NES=2.03, p.adj=0.0251), the expression of ISGs (e.g., <em>IFIT2</em>, <em>IFI27</em>, <em>IFITM1</em>, <em>IFI6</em>), and macrophage gene signatures (e.g., <em>MARCO</em>, <em>CD163</em>, <em>CD5L</em>, <em>CD63</em>), when compared to patients with ENEG alone.<h3>Conclusions</h3>Transcriptomic profiling of the liver suggests that MASH negatively impacts ISGs expression in the liver of patients with ENEG, which may affect antiviral immune pathways, viral replication and inflammatory responses resulting in an increased risk of advanced fibrosis in patients with chronic hepatitis B. Our study provides valuable insights for guiding future research aimed at developing effective, tailored strategies for managing patients with both conditions.<h3>Impact and implications</h3>In recent decades, obesity and associated health issues have reached epidemic levels, with steatotic liver disease affecting up to 30% of adults in developed countries, and this trend is also observed among chronic hepatitis B patients. Given the high and rising prevalence of steatotic liver disease and its frequent co-occurrence in chronic hepatitis B patients, it is essential to understand how conditions such as metabolic dysfunction-associated steatohepatitis (MASH) impact immune responses in the liver. This study provides unique insights into the impact of MASH on HBV antiviral immune activity in the liver of patients with chronic hepatitis B. The rising number of patients with both conditions affects treatment outcomes and highlights the urgent need for novel, tailored therapeutic strategies. Our study holds significant relevance for guiding future research on developing treatment strategies for patients with both MASH and chron
{"title":"Metabolic dysfunction-associated steatohepatitis reduces interferon and macrophage liver gene signatures in patients with chronic hepatitis B","authors":"Zgjim Osmani, Willem Pieter Brouwer, Dwin G.B. Grashof, Youkyung Lim, Michael Doukas, Harry L.A. Janssen, Harmen J.G. van de Werken, Andre Boonstra","doi":"10.1016/j.jhep.2024.10.032","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.10.032","url":null,"abstract":"<h3>Background & Aims</h3>Chronic HBV patients with concomitant metabolic dysfunction-associated steatohepatitis (MASH) have been shown to develop more advanced fibrosis faster with more severe liver disease as compared to patients with chronic HBV alone. However, our understanding of the underlying mechanisms is limited. Here we study how MASH co-morbidity impact immune activity in the liver of patients with chronic HBV infection.<h3>Methods</h3>Bulk RNA sequencing was performed on liver biopsies from patients with only MASH (n=10), only HBeAg-negative chronic HBV (ENEG; n=11), combined MASH/ENEG (n=9) and healthy controls (n=9). Biopsies with no or minimal fibrosis (≤F2) were selected to avoid confounding effects of fibrosis. We compared whole transcriptome data from patients with MASH/ENEG to those with ENEG alone to determine the impact of MASH co-morbidity on chronic hepatitis B.<h3>Results</h3>There is a high degree of overlap of liver gene expression profiles in patients with only ENEG versus those with only MASH compared to healthy controls, suggesting a largely shared mechanism of liver dysfunction and immune activity for these distinct conditions. In patients with ENEG, MASH co-morbidity significantly reduced interferon pathway activity (NES=2.03, p.adj=0.0251), the expression of ISGs (e.g., <em>IFIT2</em>, <em>IFI27</em>, <em>IFITM1</em>, <em>IFI6</em>), and macrophage gene signatures (e.g., <em>MARCO</em>, <em>CD163</em>, <em>CD5L</em>, <em>CD63</em>), when compared to patients with ENEG alone.<h3>Conclusions</h3>Transcriptomic profiling of the liver suggests that MASH negatively impacts ISGs expression in the liver of patients with ENEG, which may affect antiviral immune pathways, viral replication and inflammatory responses resulting in an increased risk of advanced fibrosis in patients with chronic hepatitis B. Our study provides valuable insights for guiding future research aimed at developing effective, tailored strategies for managing patients with both conditions.<h3>Impact and implications</h3>In recent decades, obesity and associated health issues have reached epidemic levels, with steatotic liver disease affecting up to 30% of adults in developed countries, and this trend is also observed among chronic hepatitis B patients. Given the high and rising prevalence of steatotic liver disease and its frequent co-occurrence in chronic hepatitis B patients, it is essential to understand how conditions such as metabolic dysfunction-associated steatohepatitis (MASH) impact immune responses in the liver. This study provides unique insights into the impact of MASH on HBV antiviral immune activity in the liver of patients with chronic hepatitis B. The rising number of patients with both conditions affects treatment outcomes and highlights the urgent need for novel, tailored therapeutic strategies. Our study holds significant relevance for guiding future research on developing treatment strategies for patients with both MASH and chron","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"35 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142519458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-24DOI: 10.1016/j.jhep.2024.10.029
Puru Rattan, Kianna Nguyen, Daniel D. Penrice, Davide Povero, Douglas A. Simonetto
Section snippets
Authors' contributions:
P.R., K.N.: Writing - Original Draft, Data curation, Formal Analysis; D.D.P, D.P.: Data curation, Formal Analysis, Writing - Review & Editing; D.A.S.: Conceptualization, Methodology, Formal Analysis, Writing – Review and Editing, Supervision.
Financial support:
NoneThe recently published multicenter study of Porto-Sinusoidal Vascular Disorder (PSVD) patients by Magaz and Giudicelli-Lett et al thoroughly details the clinical findings and disease progression of PSVD.1 Given the rarity of PSVD yet improved prognosis with early recognition, the authors stress the importance of clinical awareness of associated conditions to expedite diagnosis. To this point, is it important to note that PSVD has also been observed in the setting of telomere biology
Declaration of Competing Interest:
DAS is funded by National Institute of Health U01AA026886–03. DAS has consulted for Mallinckrodt, Evive, Resolution Therapeutics, BioVie, AstraZeneca, Iota and PharmaIN.
{"title":"Underrecognized Association of Porto-Sinusoidal Vascular Disorder and Telomere Biology Disorders","authors":"Puru Rattan, Kianna Nguyen, Daniel D. Penrice, Davide Povero, Douglas A. Simonetto","doi":"10.1016/j.jhep.2024.10.029","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.10.029","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors' contributions:</h2>P.R., K.N.: Writing - Original Draft, Data curation, Formal Analysis; D.D.P, D.P.: Data curation, Formal Analysis, Writing - Review & Editing; D.A.S.: Conceptualization, Methodology, Formal Analysis, Writing – Review and Editing, Supervision.</section></section><section><section><h2>Financial support:</h2>NoneThe recently published multicenter study of Porto-Sinusoidal Vascular Disorder (PSVD) patients by Magaz and Giudicelli-Lett <em>et al</em> thoroughly details the clinical findings and disease progression of PSVD.<sup>1</sup> Given the rarity of PSVD yet improved prognosis with early recognition, the authors stress the importance of clinical awareness of associated conditions to expedite diagnosis. To this point, is it important to note that PSVD has also been observed in the setting of telomere biology</section></section><section><section><h2>Declaration of Competing Interest:</h2>DAS is funded by National Institute of Health U01AA026886–03. DAS has consulted for Mallinckrodt, Evive, Resolution Therapeutics, BioVie, AstraZeneca, Iota and PharmaIN.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"64 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142488811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-24DOI: 10.1016/j.jhep.2024.10.030
Wukun Ge, Weiqin Chen, Haiyan Xie
Section snippets
Authors' contributions:
WG, WC and HX conceived and designed the study. WG and WC collected and analyzed the data. HX provided clinical expertise and interpreted the results. WG drafted the manuscript. All authors critically revised the manuscript and approved the final version.
Data Availability Statement
This data can be accessed through the FDA's FAERS Public Dashboard athttps://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html.
Funding information
The study was supported by Quzhou City Science and Technology Research Project in 2023 (Grant No. 2023k193).
{"title":"Real-World Evidence Supporting the Consensus-Driven DILI Control Compounds List: An Analysis of FAERS Data","authors":"Wukun Ge, Weiqin Chen, Haiyan Xie","doi":"10.1016/j.jhep.2024.10.030","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.10.030","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors' contributions:</h2>WG, WC and HX conceived and designed the study. WG and WC collected and analyzed the data. HX provided clinical expertise and interpreted the results. WG drafted the manuscript. All authors critically revised the manuscript and approved the final version.</section></section><section><section><h2>Data Availability Statement</h2>This data can be accessed through the FDA's FAERS Public Dashboard at<span><span>https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>.</section></section><section><section><h2>Funding information</h2>The study was supported by Quzhou City Science and Technology Research Project in 2023 (Grant No. 2023k193).</section></section><section><section><h2>Declaration of Competing Interest</h2>The authors disclose no conflicts.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"90 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142488868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Karina Raikhelson wrote the original draft, Sergey Okovityi, Dzhamal Abdurakhmanov reviewed and edited this Correspondence; All the authors approved the final manuscript.
Financial support
The authors received no financial support to produce this manuscript.
Declaration of Competing Interest
The authors declare no conflict of interest pertaining to this article.
{"title":"New nomenclature for fatty liver disease: problems of localization in the regions and the position of Russian Scientific Liver Society","authors":"Karina Raikhelson, Sergey Okovityi, Dzhamal Abdurakhmanov","doi":"10.1016/j.jhep.2024.10.023","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.10.023","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors' contributions</h2>Karina Raikhelson wrote the original draft, Sergey Okovityi, Dzhamal Abdurakhmanov reviewed and edited this Correspondence; All the authors approved the final manuscript.</section></section><section><section><h2>Financial support</h2>The authors received no financial support to produce this manuscript.</section></section><section><section><h2>Declaration of Competing Interest</h2>The authors declare no conflict of interest pertaining to this article.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"13 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142487634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-23DOI: 10.1016/j.jhep.2024.10.027
M. Dandri, L. Allweiss, B. Downie, J.J. Wallin
Section snippets
Author contributions
all authors contributed equally to the reply letter
Financial support
The study was supported by Gilead Sciences and the German Center for Infection Research (TTU Hepatitis 05.822; 05.820).
Declaration of Competing Interest
LA declares no conflict of interest. JJW and BD are employees of Gilead Sciences and holders of Gilead stock. MD: Research collaboration with Gilead Science.
{"title":"Reply to: Optimising the treatment of HDV infection: efficacy of Bulevirtide, HBV-HDV interactions and the importance of statistical methods","authors":"M. Dandri, L. Allweiss, B. Downie, J.J. Wallin","doi":"10.1016/j.jhep.2024.10.027","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.10.027","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Author contributions</h2>all authors contributed equally to the reply letter</section></section><section><section><h2>Financial support</h2>The study was supported by Gilead Sciences and the German Center for Infection Research (TTU Hepatitis 05.822; 05.820).</section></section><section><section><h2>Declaration of Competing Interest</h2>LA declares no conflict of interest. JJW and BD are employees of Gilead Sciences and holders of Gilead stock. MD: Research collaboration with Gilead Science.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"35 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142487632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：